Log In
BCIQ
Print this Print this
 

GS-101A

  Manage Alerts
Collapse Summary General Information
Company Gene Signal International S.A.
DescriptionEye drop formulation of antisense oligonucleotide targeting insulin receptor substrate 1 (IRS1) mRNA
Molecular Target Insulin receptor substrate 1 (IRS1)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase III
Standard IndicationChoroidal neovascularization (CNV)
Indication DetailsTreat neovascularization associated with graft rejection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today